Blood drawn
PreclinicalBiologic
Blood drawn is one of 75 biologic programs targeting HIV infection. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
326 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Intron a
Merck & Co.Phase 3
Sunlenca
GileadPhase 3
Hivid
CConrado Roberto Hoffmann Filho
Phase 3
Praluent
RegeneronPhase 3
PEG-Intron
Merck & Co.Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Buprenorphine/naloxone
AstellasPhase 3
TWINRIX™
GSKPhase 3
F/TAF
GileadPhase 3
F/TDF
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colon Cancer1 trial
Inflammatory Response1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Blood drawn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Rouen